BIOTECH ASSISTANT / FIELD NOTES

Sanofi ends SAR448272 STAT6 degrader program, Nurix says

Company / institutional announcement · Nurix Therapeutics

Source published: 2026-11-03

Site published: 2026-11-04 · Updated: 2026-11-04

Explore this article with AI

This source is linked automatically. Choose a question to get started.

Ask AI ↗

Findings and limitations Industry implications Related developments

What changed

Nurix said Sanofi will stop the first-in-human Phase 1 trial of oral STAT6 degrader SAR448272 and end the program. Nurix no longer expects future milestone payments or royalties from this asset, while other licensed programs remain eligible for such payments. The November 3 announcement did not disclose the reason for discontinuation.

Why it may matter

Potential business implications: The termination highlights early-stage development and partnering risks, without establishing a class-wide setback for STAT6 degraders.

The interpretation above is analysis, not a conclusion attributed to the original source.

Read the original source ↗

Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections

Protein degradation / PROTAC

Related updates

2026-11-05Amphista Therapeutics / Business Wire

Amphista previews BRD9 degradation findings and BRAMLIE trial design at ASH

Amphista announced an ASH oral presentation on AMX-883-mediated BRD9 degradation, describing disruption of hematopoietic transcriptional programs, myeloid differentiation, and reduced leukemic stem-cell frequency in experimental work. A separate abstract outlines the ongoing Phase 1 BRAMLIE study in AML and high-risk myelodysplastic syndrome. The announcement does not establish clinical efficacy for AMX-883.

Protein degradation / PROTAC Ask AI ↗

2026-11-05Nurix Therapeutics

Nurix previews updated bexobrutideg Phase 1 CLL/SLL findings for ASH

Nurix announced updated Phase 1a/1b findings for its oral BTK degrader bexobrutideg (NX-5948) in relapsed or refractory CLL/SLL. The ASH presentation will include patients previously exposed to covalent BTK inhibitors and data at the recommended Phase 2 dose of 600 mg once daily. The release describes durable activity without providing numerical response rates.

Protein degradation / PROTAC Ask AI ↗

2026-11-04Proceedings of the National Academy of Sciences / PubMed

Bispecific protein drives dual receptor degradation in mouse eye-disease models

A PNAS study reports RHV, a tetravalent bispecific protein designed to internalize and lysosomally degrade VCAM-1 and VEGFR on pathological vessels. The original abstract describes activity in mouse choroidal neovascularization models, including efficacy comparable to aflibercept at one-quarter of the molar dose. This is preclinical extracellular receptor degradation, distinct from an intracellular small-molecule PROTAC.

Protein degradation / PROTAC Ask AI ↗

Continue your research

Explore company filters, side-by-side comparisons, private bookmarks, and member discussions.

Open free member tools ↗